King Pharma Says Patent Deal Didn't Bar Skelaxin Generic

Law360, New York (January 7, 2013, 5:11 PM EST) -- Pfizer Inc. unit King Pharmaceuticals Inc. on Friday said that, contrary to complaints, a patent licensing agreement related to its Skelaxin drug, now the subject of multidistrict antitrust litigation in Tennessee, didn't prevent a generic version of the muscle relaxant from coming to market.

King Pharmaceuticals urged U.S. District Judge Curtis L. Collier to dismiss several claims brought by pharmacies and drug wholesalers related to its 2005 licensing agreement with generic-drug maker Mutual Pharmaceuticals Co. Inc. The lawsuits contend the deal was a ploy to delay...
To view the full article, register now.